XML 33 R15.htm IDEA: XBRL DOCUMENT
v3.20.1

Intangible assets | 3 Months Ended
--- | ---
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets | Intangible assets The Company's intangible as sets consist of products acquired via business combinations or asset acquisitions. The following tables summarize the Company's intangible assets for the periods ended March 31, 2020 and December 31, 2019:
|  |  | March 31, 2020
(in millions) | Estimated Life |  | Cost | Additions | Accumulated Amortization | Net
Products | 9-22 years |  | $ | 788.0 |  | $ | 10.0 |  | $ | 96.0 |  | $ | 702.0 |
Customer relationships | 8 years |  | 28.6 |  | — |  | 23.8 |  | 4.8 |
Contract development and manufacturing | 8 years |  | 5.5 |  | — |  | 4.2 |  | 1.3 |
Total intangible assets |  |  | $ | 822.1 |  | $ | 10.0 |  | $ | 124.0 |  | $ | 708.1 |
|  |  | December 31, 2019
(in millions) | Estimated Life |  | Cost | Accumulated Amortization | Net
Products | 9-22 years |  | $ | 788.0 |  | $ | 82.2 |  | $ | 705.8 |
Customer relationships | 8 years |  | 28.6 |  | 23.0 |  | $ | 5.6 |
Contract development and manufacturing | 8 years |  | 5.5 |  | 4.0 |  | $ | 1.5 |
Total intangible assets |  |  | $ | 822.1 |  | $ | 109.2 |  | $ | 712.9 |
During the three months ended March 31, 2020, the Company achieved a sales milestone that resulted in a $10.0 million obligation related to the Company's asset acquisition of raxibacumab in October 2017. The achievement of the milestone resulted in an increase to intangible assets with a corresponding increase in accounts payable. As of March 31, 2020 there are no remaining contractual obligations for sales milestones related to the raxibacumab acquisition. During the three months ended March 31, 2020 and 2019, the Company recorded amortization expense for intangible assets of $14.8 million and $14.5 million, respectively. As of March 31, 2020, the weighted average amortization period remaining for intangible assets was 13.3 years. In-process research and development (IPR&D) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. There were no changes to the Company's IPR&D assets during the three months ended March 31, 2020. Goodwill was $266.4 million and $266.6 million for the periods ended March 31, 2020 and December 31, 2019, respectively. The change in the balance during the period was due to foreign currency translation adjustments.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration